Michal Orczykowski, Marcin Kowalski, Maciej Bak, Anna Jargielo, Filip Machaj, Michal Swierczewski, Krystyna Guzek, Magdalena Topczewska, Piotr Urbanek, Bodalski Robert, Andrzej Glowniak, Pawel Derejko, Maciej Sterlinski, Maria Bilinska, Lukasz Szumowski
{"title":"心房颤动消融后射频与低温球囊180天死亡率风险:8年分析","authors":"Michal Orczykowski, Marcin Kowalski, Maciej Bak, Anna Jargielo, Filip Machaj, Michal Swierczewski, Krystyna Guzek, Magdalena Topczewska, Piotr Urbanek, Bodalski Robert, Andrzej Glowniak, Pawel Derejko, Maciej Sterlinski, Maria Bilinska, Lukasz Szumowski","doi":"10.1111/pace.15164","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Catheter ablation (CA) is a preferred treatment for atrial fibrillation (AF), often outperforming antiarrhythmic medications in maintaining sinus rhythm and managing symptoms. One of the most important features of any treatment method, alongside its effectiveness, is its safety.</p><p><strong>Methods: </strong>This study evaluates 180-day all-cause mortality rates post-ablation using data from the National Health Fund in Poland (NHF-P), encompassing over 99% of AF CAs and 100% of deaths in Poland from 2012 to 2019.</p><p><strong>Results: </strong>Our analysis, which included 31,214 ablations on 26,767 patients (34.8% female), compared cryoballoon and radiofrequency (RF) ablation techniques and assessed mortality rates and risk factors. The study revealed a 180-day mortality rate of 0.56%, with the highest rate observed in patients over 80 years old (2.67%) and the lowest in those aged 18-34 years (0.29%). Mortality did not significantly differ between cryoballoon (0.48%) and RF ablation (0.65%; p = 0.072). The risk of mortality did not differ between patients undergoing a first-time ablation and those having subsequent procedures (p = 0.90, OR 0.92). Significant risk factors for increased mortality included male sex, kidney disease, heart failure, diabetes, prior myocardial infarction, and a history of malignancy.</p><p><strong>Conclusion: </strong>The 180-day mortality rate after AF ablation procedure reached 0.56%, with no significant difference between cryoballoon and RF ablation. Further research, including matched control groups and extended follow-up periods, is essential to better understand the benefits and risks of CA for AF, particularly in the oldest patient groups.</p>","PeriodicalId":54653,"journal":{"name":"Pace-Pacing and Clinical Electrophysiology","volume":" ","pages":"363-366"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiofrequency Versus Cryoballoon 180-Day Mortality Risk After Atrial Fibrillation Ablation: An 8-Year Analysis.\",\"authors\":\"Michal Orczykowski, Marcin Kowalski, Maciej Bak, Anna Jargielo, Filip Machaj, Michal Swierczewski, Krystyna Guzek, Magdalena Topczewska, Piotr Urbanek, Bodalski Robert, Andrzej Glowniak, Pawel Derejko, Maciej Sterlinski, Maria Bilinska, Lukasz Szumowski\",\"doi\":\"10.1111/pace.15164\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Catheter ablation (CA) is a preferred treatment for atrial fibrillation (AF), often outperforming antiarrhythmic medications in maintaining sinus rhythm and managing symptoms. One of the most important features of any treatment method, alongside its effectiveness, is its safety.</p><p><strong>Methods: </strong>This study evaluates 180-day all-cause mortality rates post-ablation using data from the National Health Fund in Poland (NHF-P), encompassing over 99% of AF CAs and 100% of deaths in Poland from 2012 to 2019.</p><p><strong>Results: </strong>Our analysis, which included 31,214 ablations on 26,767 patients (34.8% female), compared cryoballoon and radiofrequency (RF) ablation techniques and assessed mortality rates and risk factors. The study revealed a 180-day mortality rate of 0.56%, with the highest rate observed in patients over 80 years old (2.67%) and the lowest in those aged 18-34 years (0.29%). Mortality did not significantly differ between cryoballoon (0.48%) and RF ablation (0.65%; p = 0.072). The risk of mortality did not differ between patients undergoing a first-time ablation and those having subsequent procedures (p = 0.90, OR 0.92). Significant risk factors for increased mortality included male sex, kidney disease, heart failure, diabetes, prior myocardial infarction, and a history of malignancy.</p><p><strong>Conclusion: </strong>The 180-day mortality rate after AF ablation procedure reached 0.56%, with no significant difference between cryoballoon and RF ablation. Further research, including matched control groups and extended follow-up periods, is essential to better understand the benefits and risks of CA for AF, particularly in the oldest patient groups.</p>\",\"PeriodicalId\":54653,\"journal\":{\"name\":\"Pace-Pacing and Clinical Electrophysiology\",\"volume\":\" \",\"pages\":\"363-366\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pace-Pacing and Clinical Electrophysiology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1111/pace.15164\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pace-Pacing and Clinical Electrophysiology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1111/pace.15164","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
导读:导管消融(CA)是房颤(AF)的首选治疗方法,在维持窦性心律和控制症状方面通常优于抗心律失常药物。任何治疗方法最重要的特点之一,除了它的有效性,就是它的安全性。方法:本研究使用波兰国家卫生基金(NHF-P)的数据评估消融术后180天的全因死亡率,包括波兰2012年至2019年99%以上的AF CAs和100%的死亡病例。结果:我们的分析包括26,767例患者(34.8%为女性)的31,214例消融,比较了冷冻球囊和射频(RF)消融技术,并评估了死亡率和危险因素。180天死亡率为0.56%,其中80岁以上患者死亡率最高(2.67%),18-34岁患者死亡率最低(0.29%)。低温球囊消融(0.48%)和射频消融(0.65%)的死亡率无显著差异;p = 0.072)。首次消融和后续消融患者的死亡风险无差异(p = 0.90, OR 0.92)。死亡率增加的重要危险因素包括男性、肾脏疾病、心力衰竭、糖尿病、既往心肌梗死和恶性肿瘤史。结论:AF消融后180天死亡率为0.56%,低温球囊消融与射频消融无显著性差异。进一步的研究,包括匹配的对照组和延长的随访期,对于更好地了解房颤CA的益处和风险至关重要,特别是在老年患者群体中。
Radiofrequency Versus Cryoballoon 180-Day Mortality Risk After Atrial Fibrillation Ablation: An 8-Year Analysis.
Introduction: Catheter ablation (CA) is a preferred treatment for atrial fibrillation (AF), often outperforming antiarrhythmic medications in maintaining sinus rhythm and managing symptoms. One of the most important features of any treatment method, alongside its effectiveness, is its safety.
Methods: This study evaluates 180-day all-cause mortality rates post-ablation using data from the National Health Fund in Poland (NHF-P), encompassing over 99% of AF CAs and 100% of deaths in Poland from 2012 to 2019.
Results: Our analysis, which included 31,214 ablations on 26,767 patients (34.8% female), compared cryoballoon and radiofrequency (RF) ablation techniques and assessed mortality rates and risk factors. The study revealed a 180-day mortality rate of 0.56%, with the highest rate observed in patients over 80 years old (2.67%) and the lowest in those aged 18-34 years (0.29%). Mortality did not significantly differ between cryoballoon (0.48%) and RF ablation (0.65%; p = 0.072). The risk of mortality did not differ between patients undergoing a first-time ablation and those having subsequent procedures (p = 0.90, OR 0.92). Significant risk factors for increased mortality included male sex, kidney disease, heart failure, diabetes, prior myocardial infarction, and a history of malignancy.
Conclusion: The 180-day mortality rate after AF ablation procedure reached 0.56%, with no significant difference between cryoballoon and RF ablation. Further research, including matched control groups and extended follow-up periods, is essential to better understand the benefits and risks of CA for AF, particularly in the oldest patient groups.
期刊介绍:
Pacing and Clinical Electrophysiology (PACE) is the foremost peer-reviewed journal in the field of pacing and implantable cardioversion defibrillation, publishing over 50% of all English language articles in its field, featuring original, review, and didactic papers, and case reports related to daily practice. Articles also include editorials, book reviews, Musings on humane topics relevant to medical practice, electrophysiology (EP) rounds, device rounds, and information concerning the quality of devices used in the practice of the specialty.